Table 7 |
|||
|
Ocular adverse events over a 6-month period from pegaptanib treatment initiation. |
|||
|
Adverse event |
Number of subjects with occurrence |
Total number of occurrences |
Rate of occurrence by number of injections* |
|
|
|||
|
Endophthalmitis |
1† |
1† |
0.003 |
|
Retinal detachment |
0 |
0 |
0 |
|
Increased intraocular pressure |
0 |
0 |
0 |
|
Retinal tear |
0 |
0 |
0 |
|
Traumatic cataract |
0 |
0 |
0 |
|
Vitreous haemorrhage |
0 |
0 |
0 |
|
Geographic atrophy |
2† |
2† |
0.006 |
|
Other |
0 |
0 |
0 |
|
|
|||
|
* Based on 326 total injections received by study subjects. † Unclear history. |
|||
|
Weber et al. BMC Ophthalmology 2010 10:2 doi:10.1186/1471-2415-10-2 |
|||
